These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32301591)

  • 1. Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis.
    Freeman MP; Fava M; Dirks B; Jha MK; Papakostas GI; Shelton RC; Thase ME; Trivedi MH; Liu K; Stankovic S
    Depress Anxiety; 2020 May; 37(5):485-495. PubMed ID: 32301591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY).
    Fava M; Dirks B; Freeman MP; Papakostas GI; Shelton RC; Thase ME; Trivedi MH; Liu K; Stankovic S
    J Clin Psychiatry; 2019 Sep; 80(6):. PubMed ID: 31556975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY.
    Jha MK; Fava M; Freeman MP; Thase ME; Papakostas GI; Shelton RC; Trivedi MH; Dirks B; Liu K; Stankovic S
    J Clin Psychiatry; 2020 Dec; 82(1):. PubMed ID: 33264819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study.
    Papakostas GI; Fava M; Freeman MP; Shelton RC; Thase ME; Jha MK; Trivedi MH; Dirks B; Liu K; Stankovic S
    Int Clin Psychopharmacol; 2020 Nov; 35(6):313-321. PubMed ID: 32804742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date.
    Soogrim V; Ruberto VL; Murrough J; Jha MK
    Drug Des Devel Ther; 2021; 15():151-157. PubMed ID: 33469267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
    Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME
    BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exposure-response Modeling From the CLARITY Trial of Pimavanserin for Adjunctive Treatment of Major Depressive Disorder.
    Darwish M; Dirks B; Passarell J; Jaworowicz D; Bihorel S; Howell B; Owen J; DeKarske D; Stankovic S
    Clin Pharmacol Drug Dev; 2023 May; 12(5):463-474. PubMed ID: 36880278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study.
    Shelton RC; Fava M; Freeman MP; Thase ME; Papakostas GI; Jha MK; Trivedi MH; Dirks B; Liu K; Stankovic S
    J Affect Disord; 2020 Dec; 277():478-485. PubMed ID: 32871535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
    Ball S; Dellva MA; D'Souza DN; Marangell LB; Russell JM; Goldberger C
    J Affect Disord; 2014; 167():215-23. PubMed ID: 24995890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of aticaprant, a kappa receptor antagonist, adjunctive to oral SSRI/SNRI antidepressant in major depressive disorder: results of a phase 2 randomized, double-blind, placebo-controlled study.
    Schmidt ME; Kezic I; Popova V; Melkote R; Van Der Ark P; Pemberton DJ; Mareels G; Canuso CM; Fava M; Drevets WC
    Neuropsychopharmacology; 2024 Aug; 49(9):1437-1447. PubMed ID: 38649428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive Pimavanserin in Patients with Major Depressive Disorder: Combined Results from Two Randomized, Double-Blind, Placebo-Controlled Phase 3 Studies.
    Dirks B; Fava M; Atkinson SD; Joyce M; Thase ME; Howell B; Lin T; Stankovic S
    Psychopharmacol Bull; 2022 Oct; 52(4):8-30. PubMed ID: 36339271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression.
    DeKarske D; Alva G; Aldred JL; Coate B; Cantillon M; Jacobi L; Nunez R; Norton JC; Abler V
    J Parkinsons Dis; 2020; 10(4):1751-1761. PubMed ID: 32804101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
    Fava M; Mischoulon D; Iosifescu D; Witte J; Pencina M; Flynn M; Harper L; Levy M; Rickels K; Pollack M
    Psychother Psychosom; 2012; 81(2):87-97. PubMed ID: 22286203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.
    Preskorn SH; Baker B; Kolluri S; Menniti FS; Krams M; Landen JW
    J Clin Psychopharmacol; 2008 Dec; 28(6):631-7. PubMed ID: 19011431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies.
    Fava M; Dording CM; Baker RA; Mankoski R; Tran QV; Forbes RA; Eudicone JM; Owen R; Berman RM
    Prim Care Companion CNS Disord; 2011; 13(1):. PubMed ID: 21731833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
    Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
    Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.